医疗机构简介
医疗机构简介
Hospitals
Hospitals
Embedded Files
博鳌超级医院Boao Super Hospital
博鳌超级医院是国有控股的三级综合医院，医院位于美丽的万泉河畔，占地面积2万平方米，开放床位150张。是海南自贸港乐城国际医疗旅游先行区开业的第一家医院，于2018年3月31日正式运营。
目前，医院拥有内科、外科、妇科、儿科、眼科、皮肤科等近30个临床医技科室，合作引进院士团队10余个。其中耳鼻喉科、眼科、皮肤科、心血管内科、肿瘤科、罕见病诊疗中心等在院士及知名专家的亲自带领下，在学科发展和特许药械的应用上处于先行区前列。
医院利用特许药械政策，通过采用“1+X”的平台型运营模式，有力地促进了业务飞速发展，造福了广大百姓。至2023年底，医院共引进特许药械155项，包括60项特许药品和95项特许器械，创造了多个“国内首例”，受益2万余人次，引领了乐城先行区的医疗技术水平。与此同时，博鳌超级医院为乐城园区内最早开展真实世界研究的医疗机构，目前共开展真实世界研究28项，通过真研上市的品种有12项，为国外先进的医疗技术和特许药械进入国内市场作出了重要贡献，缩短了我国与世界先进国家医疗技术的差距。
医院按平台型医院定位，投资2亿多元配备了国际领先的128排CT、3.0磁共振、飞利浦DSA等高端医疗设备以及数字化层流净化手术室、先进的重症监护病房等配套基础设施，有力地保障了各项尖端、前沿技术的顺利开展。
Boao Super Hospital is a state-controlled, Grade III comprehensive hospital situated along the banks of the scenic Wanquan River. Spanning an area of 20,000 square meters, the hospital features 150 inpatient beds. It was the first hospital to commence operations within the Lecheng International Medical Tourism Pilot Zone of the Hainan Free Trade Port, officially opening its doors on March 31, 2018.
Currently, the hospital houses nearly 30 clinical and technical departments—including Internal Medicine, Surgery, Gynecology, Pediatrics, Ophthalmology, and Dermatology—and has established collaborative partnerships with over 10 academician-led teams. Notably, departments such as ENT, Ophthalmology, Dermatology, Cardiovascular Medicine, Oncology, and the Rare Disease Diagnosis and Treatment Center—personally led by academicians and renowned experts—stand at the forefront of the Pilot Zone in terms of disciplinary development and the application of specially authorized pharmaceuticals and medical devices.
Leveraging the policies regarding licensed pharmaceuticals and medical devices, the hospital has adopted a "1+X" platform-based operational model. This approach has vigorously driven rapid business expansion and brought significant benefits to the general public. By the end of 2023, the hospital had introduced a total of 155 licensed medical products—comprising 60 pharmaceuticals and 95 medical devices—establishing numerous "domestic firsts." These initiatives have benefited over 20,000 patient visits, thereby setting the standard for medical technology within the Lecheng Pilot Zone. Concurrently, Boao Super Hospital was the first medical institution within the Lecheng Park to initiate "Real-World Studies" (RWS). To date, the hospital has conducted 28 such studies, 12 of which have successfully led to the market approval of medical products. This work has made significant contributions toward facilitating the entry of advanced foreign medical technologies and licensed products into the domestic market, effectively narrowing the gap between my country's medical capabilities and those of the world's leading nations.
Positioning itself as a platform-based hospital, the institution has invested over 200 million RMB to acquire internationally leading, high-end medical equipment—including a 128-slice CT scanner, a 3.0T MRI system, and a Philips DSA system—as well as supporting infrastructure such as digital laminar-flow operating rooms and advanced intensive care units. This comprehensive investment serves as a robust guarantee for the successful implementation of various cutting-edge and frontier medical technologies.
博鳌超级医院是国有控股的三级综合医院，医院位于美丽的万泉河畔，占地面积2万平方米，开放床位150张。是海南自贸港乐城国际医疗旅游先行区开业的第一家医院，于2018年3月31日正式运营。
目前，医院拥有内科、外科、妇科、儿科、眼科、皮肤科等近30个临床医技科室，合作引进院士团队10余个。其中耳鼻喉科、眼科、皮肤科、心血管内科、肿瘤科、罕见病诊疗中心等在院士及知名专家的亲自带领下，在学科发展和特许药械的应用上处于先行区前列。
医院利用特许药械政策，通过采用“1+X”的平台型运营模式，有力地促进了业务飞速发展，造福了广大百姓。至2023年底，医院共引进特许药械155项，包括60项特许药品和95项特许器械，创造了多个“国内首例”，受益2万余人次，引领了乐城先行区的医疗技术水平。与此同时，博鳌超级医院为乐城园区内最早开展真实世界研究的医疗机构，目前共开展真实世界研究28项，通过真研上市的品种有12项，为国外先进的医疗技术和特许药械进入国内市场作出了重要贡献，缩短了我国与世界先进国家医疗技术的差距。
医院按平台型医院定位，投资2亿多元配备了国际领先的128排CT、3.0磁共振、飞利浦DSA等高端医疗设备以及数字化层流净化手术室、先进的重症监护病房等配套基础设施，有力地保障了各项尖端、前沿技术的顺利开展。
Boao Super Hospital is a state-controlled, Grade III comprehensive hospital situated along the banks of the scenic Wanquan River. Spanning an area of 20,000 square meters, the hospital features 150 inpatient beds. It was the first hospital to commence operations within the Lecheng International Medical Tourism Pilot Zone of the Hainan Free Trade Port, officially opening its doors on March 31, 2018.
Currently, the hospital houses nearly 30 clinical and technical departments—including Internal Medicine, Surgery, Gynecology, Pediatrics, Ophthalmology, and Dermatology—and has established collaborative partnerships with over 10 academician-led teams. Notably, departments such as ENT, Ophthalmology, Dermatology, Cardiovascular Medicine, Oncology, and the Rare Disease Diagnosis and Treatment Center—personally led by academicians and renowned experts—stand at the forefront of the Pilot Zone in terms of disciplinary development and the application of specially authorized pharmaceuticals and medical devices.
Leveraging the policies regarding licensed pharmaceuticals and medical devices, the hospital has adopted a "1+X" platform-based operational model. This approach has vigorously driven rapid business expansion and brought significant benefits to the general public. By the end of 2023, the hospital had introduced a total of 155 licensed medical products—comprising 60 pharmaceuticals and 95 medical devices—establishing numerous "domestic firsts." These initiatives have benefited over 20,000 patient visits, thereby setting the standard for medical technology within the Lecheng Pilot Zone. Concurrently, Boao Super Hospital was the first medical institution within the Lecheng Park to initiate "Real-World Studies" (RWS). To date, the hospital has conducted 28 such studies, 12 of which have successfully led to the market approval of medical products. This work has made significant contributions toward facilitating the entry of advanced foreign medical technologies and licensed products into the domestic market, effectively narrowing the gap between my country's medical capabilities and those of the world's leading nations.
Positioning itself as a platform-based hospital, the institution has invested over 200 million RMB to acquire internationally leading, high-end medical equipment—including a 128-slice CT scanner, a 3.0T MRI system, and a Philips DSA system—as well as supporting infrastructure such as digital laminar-flow operating rooms and advanced intensive care units. This comprehensive investment serves as a robust guarantee for the successful implementation of various cutting-edge and frontier medical technologies.
您可以在此处填写主厨的简历。主厨是如何开始从事这份工作的？在哪里接受了培训？有着怎样的餐饮理念？向浏览者介绍是谁设计了餐厅的菜单和塑造了餐厅的愿景。
您可以在此处填写主厨的简历。主厨是如何开始从事这份工作的？在哪里接受了培训？有着怎样的餐饮理念？向浏览者介绍是谁设计了餐厅的菜单和塑造了餐厅的愿景。
上海交通大学医学院附属瑞金医院海南医院（海南博鳌研究型医院）Ruijin-Hainan Hospital Shanghai Jiao Tong University School of Medicine (Hainan Boao Research Hospital)
瑞金海南医院是海南省政府批准建设的国家和省级重点项目，是乐城先行区中首家公立医疗机构，一期核定床位数500张，瑞金海南医院将平移上海瑞金医院“技术、人才、管理和品牌”,聚焦肿瘤及血液学科群、心脑血管和代谢学科群、神经脑科学学科群三大学科群，建成集国家真实世界临床数据研究中心、先进技术国家医学研究中心，配备了高端先进的介入治疗 Artisone DSA 设备及集覆盖范围、空间分辨率、低剂量性能等优势于一身Revolution CT 和常规部位扫描时间节约20%的磁共振SIGNAPremier3.0T等。
Ruijin Hainan Hospital is a key national and provincial project approved by the Hainan Provincial Government, and serves as the first public medical institution within the Lecheng Pilot Zone. With an approved capacity of 500 beds in its first phase, the hospital seamlessly integrates the "technology, talent, management, and brand" of Shanghai Ruijin Hospital. It focuses on three major clusters of medical disciplines: Oncology and Hematology; Cardiovascular, Cerebrovascular, and Metabolic Diseases; and Neuroscience. The facility is being established as a comprehensive center housing both a National Real-World Clinical Data Research Center and a National Medical Research Center for Advanced Technologies. It is equipped with high-end, state-of-the-art interventional treatment systems—such as the Artis one DSA—as well as advanced diagnostic imaging equipment, including the Revolution CT (which combines superior coverage, spatial resolution, and low-dose performance) and the SIGNAPremier 3.0T MRI scanner (which reduces scanning times for routine anatomical regions by 20%).
四川大学华西乐城医院West China Lecheng Hospital, Sichuan University
该项目于2020年9月开工建设，总建筑面积约6.63万平方米，一期占地63亩，开放床位200张。依托四川大学华西医院优质资源，高水平引入15个顶尖诊疗中心，以临床应用为导向，围绕肿瘤治疗、罕见病研究、生物医药与健康、人工智能与大数据、临床真实世界数据应用等前沿领域，开展具有国际引领、探索性的临床医学研究，同时推进相关科研成果在乐城先行区得到转化，为国内外患者提供优质医疗服务
Construction on this project commenced in September 2020. With a total floor area of approximately 66,300 square meters, Phase I occupies a site of 63 mu and features 200 inpatient beds. Leveraging the high-quality resources of West China Hospital of Sichuan University, the facility has established 15 top-tier diagnostic and treatment centers. Guided by a clinical application-oriented approach, it conducts pioneering and internationally leading clinical medical research across cutting-edge fields—including oncology, rare disease research, biomedicine and healthcare, AI and big data, and the application of real-world clinical data. Concurrently, the project facilitates the translation of relevant research findings within the Lecheng Pilot Zone, thereby providing high-quality medical services to patients both domestically and abroad.
海南博鳌鲁医医院Hainan Boao LuYi Hospital
海南博鳌鲁医医院，由山东省医学会联合银丰集团设立，在肿瘤防治、医美抗衰、内科、骨科、妇科和康复医学、临床营养等优势学科，为患者提供特色高品质诊疗服务和健康管理服务。医院规划床位200张，牙椅2张，一期建筑面积为7010.90㎡，开放床位25张，二期尚未建设。医生75人，其中主任医师20人、副主任医师40人、主治医师11人、医师4人；护士22人，其中副主任护师3人、主管护师2人、护师6人、护士11人。
Hainan Boao Luyi Hospital was established jointly by the Shandong Medical Association and the Yinfeng Group. Specializing in key disciplines—including oncology prevention and treatment, medical aesthetics and anti-aging, internal medicine, orthopedics, gynecology, rehabilitation medicine, and clinical nutrition—the hospital provides patients with distinctive, high-quality diagnostic and treatment services, as well as comprehensive health management services. The hospital is planned to accommodate 200 inpatient beds and two dental chairs; Phase I currently encompasses a built-up area of 7,010.90 square meters, with 25 beds currently in operation, while Phase II has not yet been constructed. The medical staff comprises 75 physicians—including 20 Chief Physicians, 40 Associate Chief Physicians, 11 Attending Physicians, and 4 Physicians—and 22 nurses, consisting of 3 Associate Chief Nurses, 2 Supervising Nurses, 6 Senior Nurses, and 11 Staff Nurses.
博鳌一龄生命养护中心Boao Yiling Life Care Center
博鳌一龄生命养护中心占地面积56亩，建筑面积66710平方米。经过多年的发展，已经形成了以健康美丽幸福为主题、以现代医疗健康服务为业务定位，横跨预防医学、慢性疾病管理、康复医学、老龄医学、老年病学、精准医学等多学科、多专业、多元化的综合性医疗康养服务机构。提供“医养结合、医旅融合”的医疗服务：精准检测、预测、预防、干预服务；亚健康管理、慢病管理、健康促进、健康状况改善服务；脑健康、眼健康、肺健康、心脑血管、肌骨与运动、免疫与肿瘤、男性女性生殖健康、代谢健康、消化健康、口腔健康等疾病预防服务；国内国际转诊服务；魅力形象设计打造、形象托管服务；医美整形、综合抗衰服务、女性两癌筛查与预防服务；心灵瑜伽、心灵禅修、心理调适、幸福心世界构建等心身养护服务；中华优秀传统文化、琴棋书画、茶道、香道、插花艺术、艺术品鉴赏、咖啡、红酒等文化体验服务；国际先进的新型医疗技术、医疗器械和药品在先行区的特许医疗、特许研究、特许经营服务；医疗旅游、休闲度假服务等。
Boao Yiling Life Care Center spans a land area of 56 mu, with a total floor area of 66,710 square meters. Through years of development, it has evolved into a comprehensive medical and wellness institution centered on the themes of health, beauty, and happiness, and positioned around modern medical and health services. Its scope encompasses a multidisciplinary, multi-specialty, and diversified range of fields, including preventive medicine, chronic disease management, rehabilitative medicine, geriatric medicine, precision medicine, and more. The Center offers medical services characterized by the integration of "medical care with wellness" and "medical care with tourism," including: precision diagnostics, risk prediction, disease prevention, and intervention services; management of sub-health conditions and chronic diseases, health promotion, and health improvement services; disease prevention services targeting specific areas such as brain, eye, and lung health, cardiovascular and cerebrovascular systems, musculoskeletal and sports medicine, immunology and oncology, male and female reproductive health, metabolic health, digestive health, and oral health; domestic and international medical referral services; personal image design, styling, and image management services; medical aesthetics and plastic surgery, comprehensive anti-aging services, and screening and prevention services for common female cancers; mind-body wellness services—such as therapeutic yoga, Zen meditation, psychological adjustment, and the cultivation of a "happy inner world"; cultural experience services featuring excellent traditional Chinese culture—including *qin* (zither), *qi* (Go), calligraphy, painting, tea ceremonies, incense ceremonies, floral art, art appreciation, as well as coffee and fine wine experiences; and—within the designated Pilot Zone—authorized medical treatment, research, and operational services utilizing advanced international medical technologies, devices, and pharmaceuticals; as well as medical tourism and leisure vacation services.
海南梅赛尔医院Hainan Mellsser Hospital
2023年3月18日，以精准体检、心脑血管疾病防治、慢病管理、医疗美容、康复疗养和健康管理为主的梅赛尔医院在海南博鳌乐城国际医疗旅游先行区建成开业。梅赛尔医院设有六大板块、十八个特色科室，涵盖精准体检至医疗美容等多元化领域。通过与费森尤斯集团、华医心诚、妙佑医疗国际及日本小田医院等国际顶尖机构合作，医院建立了包括心脏康复中心和精准心血管内科在内的高端医疗体系，配备先进检测设备，汇聚全球医学精英，为全球会员提供国际一流的一站式健康管理解决方案。
On March 18, 2023, Messer Hospital—a facility specializing in precision health screenings, the prevention and treatment of cardiovascular and cerebrovascular diseases, chronic disease management, medical aesthetics, rehabilitation and recuperation, and general health management—was completed and opened within the Boao Lecheng International Medical Tourism Pilot Zone in Hainan. Messer Hospital comprises six major divisions and eighteen specialized departments, covering a diverse spectrum of fields ranging from precision health screenings to medical aesthetics. Through collaborations with leading international institutions—including the Fresenius Group, Huayi Xincheng, Mayo Clinic, and Japan’s Oda Hospital—the hospital has established a high-end medical ecosystem that features facilities such as a Cardiac Rehabilitation Center and a Precision Cardiovascular Medicine Department. Equipped with advanced diagnostic technology and staffed by a global assembly of medical elites, the hospital delivers world-class, one-stop health management solutions to its members worldwide.
On March 18, 2023, Messer Hospital—a facility specializing in precision health screenings, the prevention and treatment of cardiovascular and cerebrovascular diseases, chronic disease management, medical aesthetics, rehabilitation and recuperation, and general health management—was completed and opened within the Boao Lecheng International Medical Tourism Pilot Zone in Hainan. Messer Hospital comprises six major divisions and eighteen specialized departments, covering a diverse spectrum of fields ranging from precision health screenings to medical aesthetics. Through collaborations with leading international institutions—including the Fresenius Group, Huayi Xincheng, Mayo Clinic, and Japan’s Oda Hospital—the hospital has established a high-end medical ecosystem that features facilities such as a Cardiac Rehabilitation Center and a Precision Cardiovascular Medicine Department. Equipped with advanced diagnostic technology and staffed by a global assembly of medical elites, the hospital delivers world-class, one-stop health management solutions to its members worldwide.
树兰博鳌医院 Shulan (Boao) Hospital
树兰（博鳌）医院隶属于树兰医疗集团，按照三级甲等标准筹备建造，采取“一个共享医院（平台）+若干个临床医学中心”的“1+X”共享医院模式进行运营，旨在成为一个以肝病、肿瘤、罕见病、抗衰老治疗及高端康复服务为重点的综合医院。医院着力打造标准化肝病诊治中心、国际肝胰肿瘤诊治中心、国际肾脏病诊疗中心、国际听觉创新研究中心、、国际肿瘤诊治中心、医康养融合基地、国际医美中心、国际抗过敏中心八大医学中心，以及国家药监局药品医疗器械监管科学研究、海口国家高新区树兰博鳌生物医药转化研究、国际创新药械及医疗技术培训三大基地，为人民群众的健康保驾护航。内设科室：传染科、内科*、呼吸内科、肾病学科、风湿免疫科、普通外科*、骨科专业、妇科、眼科、耳鼻咽喉科*、肿瘤科*、麻醉科、医学检验科、超声科、中医科、预防保健科等。
Shulan (Bo'ao) Hospital is affiliated with the Shulan Medical Group. Constructed and prepared in accordance with Grade 3, Class A standards, the hospital operates under a "1+X" shared hospital model—comprising "one shared hospital (platform) plus multiple clinical medical centers." Its mission is to serve as a comprehensive hospital with a primary focus on liver diseases, oncology, rare diseases, anti-aging therapies, and high-end rehabilitation services. The hospital is dedicated to establishing eight major medical centers: a Standardized Center for Liver Disease Diagnosis and Treatment, an International Center for Hepato-Pancreatic Oncology, an International Center for Nephrology, an International Center for Auditory Innovation Research, an International Oncology Center, an Integrated Medical-Rehabilitation-Geriatric Care Base, an International Medical Aesthetics Center, and an International Anti-Allergy Center. Furthermore, it hosts three key bases: a Research Base for Regulatory Science of Drugs and Medical Devices (under the National Medical Products Administration), a Biomedical Translation Research Base (located within the Haikou National High-tech Zone), and a Training Base for International Innovative Drugs, Devices, and Medical Technologies—all dedicated to safeguarding the health and well-being of the public.Internal Departments:Infectious Diseases, Internal Medicine*, Respiratory Medicine, Nephrology, Rheumatology & Immunology, General Surgery*, Orthopedics, Gynecology, Ophthalmology, Otorhinolaryngology (ENT)*, Oncology*, Anesthesiology, Medical Laboratory, Ultrasound, Traditional Chinese Medicine, Preventive Healthcare, etc.
Shulan (Bo'ao) Hospital is affiliated with the Shulan Medical Group. Constructed and prepared in accordance with Grade 3, Class A standards, the hospital operates under a "1+X" shared hospital model—comprising "one shared hospital (platform) plus multiple clinical medical centers." Its mission is to serve as a comprehensive hospital with a primary focus on liver diseases, oncology, rare diseases, anti-aging therapies, and high-end rehabilitation services. The hospital is dedicated to establishing eight major medical centers: a Standardized Center for Liver Disease Diagnosis and Treatment, an International Center for Hepato-Pancreatic Oncology, an International Center for Nephrology, an International Center for Auditory Innovation Research, an International Oncology Center, an Integrated Medical-Rehabilitation-Geriatric Care Base, an International Medical Aesthetics Center, and an International Anti-Allergy Center. Furthermore, it hosts three key bases: a Research Base for Regulatory Science of Drugs and Medical Devices (under the National Medical Products Administration), a Biomedical Translation Research Base (located within the Haikou National High-tech Zone), and a Training Base for International Innovative Drugs, Devices, and Medical Technologies—all dedicated to safeguarding the health and well-being of the public.Internal Departments:Infectious Diseases, Internal Medicine*, Respiratory Medicine, Nephrology, Rheumatology & Immunology, General Surgery*, Orthopedics, Gynecology, Ophthalmology, Otorhinolaryngology (ENT)*, Oncology*, Anesthesiology, Medical Laboratory, Ultrasound, Traditional Chinese Medicine, Preventive Healthcare, etc.
颖奕国际医疗中心Enhance International Medical Center
颖奕国际医疗中心（Enhance International Medical Center）是乐城先行区内一所占地80亩、总建筑面积63000㎡的全台资三级综合医院，目前拥有300张床位、医学影像中心、A级层流手术室、cGMP实验室等。主要建设科室：运动医学及康复中心、预防医学中心、健康管理中心、抗衰及医疗美容中心、慢病管理中心。颖奕运动医学及康复中心引进美国的PRP技术设备，PRP技术针对运动损伤的早期疾病疗效显著，广泛应用于骨软骨损伤、肌腱、韧带的慢性炎症；提供运动相关的医学治疗、康复、运动心理学、预防医学以及营养指导等完整的医疗服务，拥有最高等级建设的百级层流手术室、美国锐适关节镜系统等；运动医学及康复中心还与美国Regenexx Corporate开展合作，双方计划共建Regenexx亚洲中心，在乐城国际医疗旅游先行区的政策下，开展特许药械治疗，将其临床技术应用于国内及周边国家。其中，骨软骨损伤的治疗是Regenexx的特色优势
Enhance International Medical Center is a wholly Taiwan-funded, Level III comprehensive hospital situated within the Lecheng Pilot Zone. Spanning a site area of 80 mu with a total floor area of 63,000 square meters, the facility currently features 300 inpatient beds, a medical imaging center, Class A laminar flow operating rooms, a cGMP-compliant laboratory, and other advanced amenities. Its primary clinical departments include the Center for Sports Medicine and Rehabilitation, the Center for Preventive Medicine, the Health Management Center, the Center for Anti-Aging and Medical Aesthetics, and the Center for Chronic Disease Management. The Enhance Center for Sports Medicine and Rehabilitation has introduced PRP technology and equipment from the United States. This PRP technology demonstrates significant therapeutic efficacy in the early-stage treatment of sports-related injuries and is widely applied in cases involving osteochondral lesions as well as chronic inflammation of tendons and ligaments. The Center provides a comprehensive suite of medical services—including sports-related medical treatment, rehabilitation, sports psychology, preventive medicine, and nutritional guidance—and is equipped with top-tier facilities such as Class 100 laminar flow operating rooms and the U.S.-made Arthrex arthroscopy system. Furthermore, the Center for Sports Medicine and Rehabilitation has established a partnership with Regenexx Corporate (USA); the two parties plan to jointly establish the "Regenexx Asia Center." Operating under the policy framework of the Lecheng International Medical Tourism Pilot Zone, this joint venture will offer treatments utilizing authorized pharmaceuticals and medical devices, thereby applying their advanced clinical techniques to patients within China and neighboring countries. Notably, the treatment of osteochondral lesions constitutes a core area of expertise and a distinct advantage for Regenexx.
Enhance International Medical Center is a wholly Taiwan-funded, Level III comprehensive hospital situated within the Lecheng Pilot Zone. Spanning a site area of 80 mu with a total floor area of 63,000 square meters, the facility currently features 300 inpatient beds, a medical imaging center, Class A laminar flow operating rooms, a cGMP-compliant laboratory, and other advanced amenities. Its primary clinical departments include the Center for Sports Medicine and Rehabilitation, the Center for Preventive Medicine, the Health Management Center, the Center for Anti-Aging and Medical Aesthetics, and the Center for Chronic Disease Management. The Enhance Center for Sports Medicine and Rehabilitation has introduced PRP technology and equipment from the United States. This PRP technology demonstrates significant therapeutic efficacy in the early-stage treatment of sports-related injuries and is widely applied in cases involving osteochondral lesions as well as chronic inflammation of tendons and ligaments. The Center provides a comprehensive suite of medical services—including sports-related medical treatment, rehabilitation, sports psychology, preventive medicine, and nutritional guidance—and is equipped with top-tier facilities such as Class 100 laminar flow operating rooms and the U.S.-made Arthrex arthroscopy system. Furthermore, the Center for Sports Medicine and Rehabilitation has established a partnership with Regenexx Corporate (USA); the two parties plan to jointly establish the "Regenexx Asia Center." Operating under the policy framework of the Lecheng International Medical Tourism Pilot Zone, this joint venture will offer treatments utilizing authorized pharmaceuticals and medical devices, thereby applying their advanced clinical techniques to patients within China and neighboring countries. Notably, the treatment of osteochondral lesions constitutes a core area of expertise and a distinct advantage for Regenexx.
海南启研医院Hainan Beautech Hospital
海南启研医院，是由中信产业基金（CITIC PE）投资， 美丽田园（Beauty Farm）旗下的专业健康管理抗衰机构。是一家整合国际先行医疗技术资源与权威医学专家团队的医疗抗衰机构。汇集德国、日本、瑞士、美国等权威临床医学专家与技术研发人员，以再生医学、功能医学为核心技术，在特许医疗、健康管理、医学美容和抗衰老、第三方医学检测四个方面与国际领先的医疗机构合作，开展高端抗衰服务业务、培训交流，提供精准医疗、个体化、全面健康管理。医院位于海南博鳌乐城国际医疗旅游先行区内，为第一批进驻先行区的医疗机构，是一所定位为服务于国内外高端医疗旅游及商务人群的集医、养、教、研为一体的国际化三级综合医院。医院总占地面积36亩，首期建筑面积22000平米，投资规模5亿元。目前可提供再生医学技术、功能医学技术、整形美容技术、血液血管修复技术、血液血管清理技术、运动损伤康复技术、心理情绪调理、美容抗衰排毒、男性性功能障碍调理、国际新特药等世界尖端前沿的医疗服务。具有开展包括欧盟及FDA已批准但未在国内上市的肿瘤药、疫苗、细胞临床运用等前沿技术研究的实力及团队支持，让客户不出国门即可享受国际最前沿医疗服务。同时，在北京、上海、武汉、重庆、深圳设立5个启研医疗中心，构建覆盖全国的医疗健康管理服务体系。启研医院是一家以增龄科学（Geroscience）为指导的三级综合医院，位于博鳌乐城国际医疗旅游先行区内，在全国范围内另设有8大医疗中心、启研生物科技及香港启研医疗。启研医疗特聘美国、加拿大、德国、马来西亚、中国、中国香港、中国台湾等多位医生坐诊，并与国际细胞医学专家兰迪·谢克曼共建诺奖工作站，现已被评为国家高新技术企业特色优势
Hainan Beautech Hospital is a specialized health management and anti-aging institution invested in by CITIC Private Equity (CITIC PE) and operating under the Beauty Farm brand. It is a medical anti-aging facility that integrates cutting-edge international medical technologies with a team of authoritative medical experts. Bringing together leading clinical specialists and R&D personnel from Germany, Japan, Switzerland, and the United States—and centering its practice on regenerative medicine and functional medicine—the institution collaborates with world-leading medical organizations across four key areas: licensed medical services, health management, medical aesthetics and anti-aging, and third-party medical diagnostics. Through these partnerships, it delivers high-end anti-aging services, facilitates professional training and exchanges, and provides precision medicine, personalized care, and comprehensive health management solutions. Located within the Hainan Boao Lecheng International Medical Tourism Pilot Zone—and among the very first medical institutions to establish a presence there—this facility is an international, tertiary-level general hospital. It is strategically positioned to serve a high-end clientele comprising both domestic and international medical tourists and business professionals, integrating medical treatment, wellness care, education, and research into a single comprehensive entity. The hospital occupies a total land area of 36 mu, with a first-phase construction area of 22,000 square meters and an investment scale of 500 million RMB. Currently, it offers a suite of world-class, cutting-edge medical services, including regenerative medicine, functional medicine, plastic and aesthetic surgery, vascular repair and cleansing therapies, sports injury rehabilitation, psychological and emotional wellness, anti-aging and detoxification treatments, male sexual health management, and access to novel international pharmaceuticals. Supported by a highly capable team and robust infrastructure, the hospital possesses the capacity to conduct frontier research and clinical applications—including the use of oncology drugs, vaccines, and cell therapies that have received approval from the EU and the FDA but are not yet commercially available within China—thereby enabling clients to access the world's most advanced medical services without ever having to travel abroad. Furthermore, the hospital has established five "Qiyan Medical Centers" across Beijing, Shanghai, Wuhan, Chongqing, and Shenzhen, thereby constructing a nationwide medical and health management service network.It's a tertiary general hospital guided by the principles of Geroscience, situated within the Boao Lecheng International Medical Tourism Pilot Zone. Its network extends nationwide, comprising eight additional medical centers, Qiyan Biotechnology, and Qiyan Medical (Hong Kong). Qiyan Medical has specially engaged a distinguished roster of physicians from the United States, Canada, Germany, Malaysia, mainland China, Hong Kong, and Taiwan to provide clinical services; furthermore, it has established a Nobel Laureate Workstation in collaboration with renowned international cellular medicine expert Randy Schekman. The institution has been officially recognized as a National High-tech Enterprise.
Hainan Beautech Hospital is a specialized health management and anti-aging institution invested in by CITIC Private Equity (CITIC PE) and operating under the Beauty Farm brand. It is a medical anti-aging facility that integrates cutting-edge international medical technologies with a team of authoritative medical experts. Bringing together leading clinical specialists and R&D personnel from Germany, Japan, Switzerland, and the United States—and centering its practice on regenerative medicine and functional medicine—the institution collaborates with world-leading medical organizations across four key areas: licensed medical services, health management, medical aesthetics and anti-aging, and third-party medical diagnostics. Through these partnerships, it delivers high-end anti-aging services, facilitates professional training and exchanges, and provides precision medicine, personalized care, and comprehensive health management solutions. Located within the Hainan Boao Lecheng International Medical Tourism Pilot Zone—and among the very first medical institutions to establish a presence there—this facility is an international, tertiary-level general hospital. It is strategically positioned to serve a high-end clientele comprising both domestic and international medical tourists and business professionals, integrating medical treatment, wellness care, education, and research into a single comprehensive entity. The hospital occupies a total land area of 36 mu, with a first-phase construction area of 22,000 square meters and an investment scale of 500 million RMB. Currently, it offers a suite of world-class, cutting-edge medical services, including regenerative medicine, functional medicine, plastic and aesthetic surgery, vascular repair and cleansing therapies, sports injury rehabilitation, psychological and emotional wellness, anti-aging and detoxification treatments, male sexual health management, and access to novel international pharmaceuticals. Supported by a highly capable team and robust infrastructure, the hospital possesses the capacity to conduct frontier research and clinical applications—including the use of oncology drugs, vaccines, and cell therapies that have received approval from the EU and the FDA but are not yet commercially available within China—thereby enabling clients to access the world's most advanced medical services without ever having to travel abroad. Furthermore, the hospital has established five "Qiyan Medical Centers" across Beijing, Shanghai, Wuhan, Chongqing, and Shenzhen, thereby constructing a nationwide medical and health management service network.It's a tertiary general hospital guided by the principles of Geroscience, situated within the Boao Lecheng International Medical Tourism Pilot Zone. Its network extends nationwide, comprising eight additional medical centers, Qiyan Biotechnology, and Qiyan Medical (Hong Kong). Qiyan Medical has specially engaged a distinguished roster of physicians from the United States, Canada, Germany, Malaysia, mainland China, Hong Kong, and Taiwan to provide clinical services; furthermore, it has established a Nobel Laureate Workstation in collaboration with renowned international cellular medicine expert Randy Schekman. The institution has been officially recognized as a National High-tech Enterprise.
海南博鳌乐城爱尔眼科医院International Clinical Research Center
爱尔眼科医院集团是具有中国及全球范围医院规模和优质医疗能力的眼科医疗集团，服务覆盖亚洲、欧洲和北美洲，在中国内地、欧洲、东南亚拥有3家上市公司(中国A股：爱尔眼科，300015;西班牙：CBAV;新加坡：40T)。目前在全球范围内开设眼科医院及中心达720家，其中中国内地611家、中国香港7家、美国1家、欧洲89家、东南亚12家。2020年，中国内地年门诊量超1000万人次，手术量超100万台，医疗服务网络覆盖全球近30亿人口。爱尔眼科将将借助乐城先行区的特许政策开展高端特许眼科医疗服务，着力打造集临床、教学、科研、创新孵化于一体的国际临床研究基地，通过为患者提供和使用海外新批复的新药、新器械和新设备，为创新型药械在国内的全面应用积累经验，将医院建设成为“国际+国内眼科资源双循环交汇点”。
Aier Eye Hospital Group is a leading ophthalmic healthcare group distinguished by its extensive hospital network and high-quality medical capabilities, spanning both China and the global stage. Its services extend across Asia, Europe, and North America, and the Group currently holds listings on three stock exchanges: in mainland China (A-share: Aier Eye Hospital, 300015), Spain (CBAV), and Singapore (40T). To date, the Group has established a global network comprising 720 ophthalmic hospitals and centers—including 611 in mainland China, 7 in Hong Kong, 1 in the United States, 89 in Europe, and 12 in Southeast Asia. In 2020, the Group’s facilities in mainland China recorded an annual outpatient volume exceeding 10 million visits and performed over 1 million surgical procedures, with its medical service network reaching a global population of nearly 3 billion people. Leveraging the preferential policies of the Lecheng Pilot Zone, Aier Eye Hospital is poised to launch high-end, specialized ophthalmic medical services. The Group aims to establish an international clinical research hub that seamlessly integrates clinical practice, medical education, scientific research, and innovation incubation. By facilitating patient access to newly approved overseas drugs, medical devices, and equipment, the Group seeks to accumulate valuable experience for the broader domestic application of innovative medical technologies, thereby transforming the hospital into a pivotal "nexus for the dual circulation of international and domestic ophthalmic resources."
Aier Eye Hospital Group is a leading ophthalmic healthcare group distinguished by its extensive hospital network and high-quality medical capabilities, spanning both China and the global stage. Its services extend across Asia, Europe, and North America, and the Group currently holds listings on three stock exchanges: in mainland China (A-share: Aier Eye Hospital, 300015), Spain (CBAV), and Singapore (40T). To date, the Group has established a global network comprising 720 ophthalmic hospitals and centers—including 611 in mainland China, 7 in Hong Kong, 1 in the United States, 89 in Europe, and 12 in Southeast Asia. In 2020, the Group’s facilities in mainland China recorded an annual outpatient volume exceeding 10 million visits and performed over 1 million surgical procedures, with its medical service network reaching a global population of nearly 3 billion people. Leveraging the preferential policies of the Lecheng Pilot Zone, Aier Eye Hospital is poised to launch high-end, specialized ophthalmic medical services. The Group aims to establish an international clinical research hub that seamlessly integrates clinical practice, medical education, scientific research, and innovation incubation. By facilitating patient access to newly approved overseas drugs, medical devices, and equipment, the Group seeks to accumulate valuable experience for the broader domestic application of innovative medical technologies, thereby transforming the hospital into a pivotal "nexus for the dual circulation of international and domestic ophthalmic resources."
海南木棉花生殖与遗传医院Hainan Kapok Reproductive and Genetic Hospital
海南木棉花生殖与遗传医院是木棉花生殖连锁集团投资建设的：木棉花生殖与遗传医院坐落于环境优美的海南博鳌乐城国际医疗先行区。该园区于2013年2月由国务院正式批复设立，并给予了“国九条”支持政策，即特许医疗、特许经营、特许研究、特许国际交流等多项含金量极高的改革试点。2024年，木棉花生殖与遗传医院获批三级医院资质、人类辅助生殖技术服务资质，成为国内为数不多取得“三代试管婴儿”资质的医疗机构。目前已顺利接诊，为患者提供合法合规的生殖相关诊疗服务。
The Kapok Reproductive and Genetic Hospital—invested in and constructed by the Kapok Reproductive Chain Group—is situated within the scenic Boao Lecheng International Medical Tourism Pilot Zone in Hainan. This zone was officially approved for establishment by the State Council in February 2013 and was granted the "Nine National Policies" of support—a series of high-value reform pilot initiatives encompassing licensed medical practice, business operations, research, and international exchange.In 2024, the Kapok Reproductive and Genetic Hospital was officially accredited as a Grade III hospital and authorized to provide human assisted reproductive technology services, thereby becoming one of the few medical institutions in China qualified to perform "Third-Generation IVF." The hospital has now successfully commenced operations, providing patients with fully legal and compliant diagnostic and treatment services related to reproductive health.
The Kapok Reproductive and Genetic Hospital—invested in and constructed by the Kapok Reproductive Chain Group—is situated within the scenic Boao Lecheng International Medical Tourism Pilot Zone in Hainan. This zone was officially approved for establishment by the State Council in February 2013 and was granted the "Nine National Policies" of support—a series of high-value reform pilot initiatives encompassing licensed medical practice, business operations, research, and international exchange.In 2024, the Kapok Reproductive and Genetic Hospital was officially accredited as a Grade III hospital and authorized to provide human assisted reproductive technology services, thereby becoming one of the few medical institutions in China qualified to perform "Third-Generation IVF." The hospital has now successfully commenced operations, providing patients with fully legal and compliant diagnostic and treatment services related to reproductive health.
永远幸（海南）医院Towako (Hainan) Hospital
永远幸（海南）医院是日本永远幸医疗集团旗下的第十八家连锁医疗机构，位于海南省琼海市博鳌乐城国际医疗旅游先行区的国际医学产业中心D栋1层。作为全球领先的全产业链辅助生殖集团，永远幸集团以其卓越的医疗服务享誉全球。海南永远幸医院秉承了集团一贯的高品质医疗服务理念，严格遵循国际JCI标准进行建设和运营。在硬件投入方面，医院配备了日本先进的实验室、手术室和妇科诊疗设备，以确保为不孕不育患者提供最精细和个性化的助孕治疗方案。同时利用海南博鳌乐城国际医疗旅游先行区的独特政策，将国际上最新的技术、药械应用到本院，全面与国际接轨。通过与日本总部的人才培训、医生交流、定期会诊和联合科研，基本实现了国际品牌、技术、服务和管理的本土化，充分贯彻“少用药，少检查、低副作用、低并发症和高卵子利用率、高胚胎质量、高舒适度”的个体化治疗的服务模式
It is the 18th medical facility within the Eienkou Medical Group of Japan. It is situated on the first floor of Building D, International Medical Industry Center, within the Boao Lecheng International Medical Tourism Pilot Zone in Qionghai City, Hainan Province. As a globally leading group encompassing the entire value chain of assisted reproductive technology, the Eienkou Group is renowned worldwide for its exceptional medical services.Hainan Eienkou Hospital upholds the Group's consistent philosophy of high-quality medical care, strictly adhering to international JCI standards in both its construction and operations. In terms of infrastructure and equipment, the hospital is outfitted with advanced Japanese laboratory, surgical, and gynecological diagnostic facilities, ensuring the provision of the most precise and personalized assisted reproductive treatment plans for patients facing infertility. Simultaneously, by leveraging the unique policy advantages of the Boao Lecheng International Medical Tourism Pilot Zone in Hainan, the hospital integrates the latest international technologies, pharmaceuticals, and medical devices into its practice, thereby achieving full alignment with global medical standards.Through collaborative initiatives with its headquarters in Japan—including personnel training, physician exchanges, regular joint consultations, and collaborative research—the hospital has effectively localized the Group's international branding, technology, services, and management practices. This approach fully embodies a personalized treatment model characterized by "minimal medication, minimal diagnostic testing, low side effects, and low complication rates," while simultaneously achieving "high oocyte utilization rates, high embryo quality, and a high level of patient comfort."
It is the 18th medical facility within the Eienkou Medical Group of Japan. It is situated on the first floor of Building D, International Medical Industry Center, within the Boao Lecheng International Medical Tourism Pilot Zone in Qionghai City, Hainan Province. As a globally leading group encompassing the entire value chain of assisted reproductive technology, the Eienkou Group is renowned worldwide for its exceptional medical services.Hainan Eienkou Hospital upholds the Group's consistent philosophy of high-quality medical care, strictly adhering to international JCI standards in both its construction and operations. In terms of infrastructure and equipment, the hospital is outfitted with advanced Japanese laboratory, surgical, and gynecological diagnostic facilities, ensuring the provision of the most precise and personalized assisted reproductive treatment plans for patients facing infertility. Simultaneously, by leveraging the unique policy advantages of the Boao Lecheng International Medical Tourism Pilot Zone in Hainan, the hospital integrates the latest international technologies, pharmaceuticals, and medical devices into its practice, thereby achieving full alignment with global medical standards.Through collaborative initiatives with its headquarters in Japan—including personnel training, physician exchanges, regular joint consultations, and collaborative research—the hospital has effectively localized the Group's international branding, technology, services, and management practices. This approach fully embodies a personalized treatment model characterized by "minimal medication, minimal diagnostic testing, low side effects, and low complication rates," while simultaneously achieving "high oocyte utilization rates, high embryo quality, and a high level of patient comfort."
博鳌国际医院Boao International Hospital
上海中医药大学博鳌国际医院按照三级综合医院标准建设，集医、教、研、抗衰、康养为一体，以生物医药新技术和再生医学为核心。医院总占地面积81.6亩，总建筑面积6.5万平方米，核定病床数560张。医院由住院大楼、门诊楼、国际再生医学研究中心、VIP康复疗养区组成。开设了国际再生医学研究中心、医学美容科、肿瘤科、内科、外科、眼科、妇科、皮肤科、中医科、健康体检科、中西药房等科室。博鳌国际医院始终坚持临床与科研并重，“人才强院”的服务宗旨，与日本医疗法人医进会小田医院、上海中医药大学、意大利都灵大学、美国斯坦福大学等多个医疗机构建立了密切的合作关系，积极引进国际先进医疗技术、设备和医学专家团队，为患者提供全生命周期的健康管理服务。Constructed in accordance with the standards for a Grade III comprehensive hospital, Shanghai University of Traditional Chinese Medicine Boao International Hospital integrates clinical care, education, research, anti-aging therapies, and wellness services, with a core focus on cutting-edge biomedical technologies and regenerative medicine. The hospital occupies a total land area of 81.6 mu and a total floor area of 65,000 square meters, with an authorized capacity of 560 inpatient beds. The facility comprises an Inpatient Building, an Outpatient Building, an International Regenerative Medicine Research Center, and a VIP Rehabilitation and Wellness Zone. It houses a comprehensive range of departments, including the International Regenerative Medicine Research Center, Medical Aesthetics, Oncology, Internal Medicine, Surgery, Ophthalmology, Gynecology, Dermatology, Traditional Chinese Medicine, Health Screening, and Western and Traditional Chinese Medicine Pharmacies.Boao International Hospital consistently prioritizes the equal importance of clinical practice and scientific research, adhering to the service philosophy of "strengthening the hospital through talent." It has established close collaborative partnerships with numerous medical institutions—including the Japanese Medical Corporation Ishinkai Oda Hospital, Shanghai University of Traditional Chinese Medicine, the University of Turin (Italy), and Stanford University (USA)—actively introducing advanced international medical technologies, equipment, and expert teams to provide patients with comprehensive, life-cycle health management services.
博鳌未来医院Boao Worldlight Hospital
博鳌未来医院成立于2015年，是博鳌乐城国际医疗旅游先行区首批入驻并开业的医疗机构。总投资4亿元，项目占地40亩，建筑面积26841㎡，设置床位200张。经海南省卫健委审批按三级医院管理，设置科室有:预防保健科、内科、外科、妇产科(妇科专业)、儿科、医疗美容科、医学检验科、医学影像科、中医科、健康体检中心、肿瘤科、精神科。未来医院专注于肿瘤精准治疗、儿童青少年心理健康治疗等精准医疗服务，以及抗衰、医美、康养、慢病管理、早期癌症筛查等健康管理服务。未来医院致力于成为中国领先的精准医学研究型医院，以“开发和引进疾病突破性精准疗法，细胞治疗技术创新，造福全人类”为使命，秉持开放、共享、共赢的态度，依托自主研发以及与全球创新医疗生物药械企业一起，加快推进创新药械和精准医疗技术的临床转化与落地，以满足民众不断增长的医疗、康养、抗衰需求和就医体验，助力中国精准医疗事业健康可持续性发展。Established in 2015, Boao Future Hospital was among the first medical institutions to be established and commence operations within the Boao Lecheng International Medical Tourism Pilot Zone. With a total investment of 400 million RMB, the facility occupies a site of 40 mu (approximately 2.67 hectares) and features a total floor area of 26,841 square meters, housing 200 inpatient beds.Approved by the Hainan Provincial Health Commission, the hospital operates under the administrative standards of a Grade III hospital. Its clinical departments and centers include Preventive Healthcare, Internal Medicine, Surgery, Obstetrics and Gynecology (Gynecology Specialty), Pediatrics, Medical Aesthetics, Clinical Laboratory, Medical Imaging, Traditional Chinese Medicine, a Health Examination Center, Oncology, and Psychiatry. Future Hospital specializes in precision medical services—such as precision oncology treatment and mental health care for children and adolescents—as well as comprehensive health management services, including anti-aging therapies, medical aesthetics, wellness and rehabilitation, chronic disease management, and early cancer screening.Future Hospital is dedicated to becoming a leading research-oriented hospital in the field of precision medicine in China. Guided by the mission to "develop and introduce groundbreaking precision therapies for diseases, innovate in cell therapy technologies, and benefit all of humanity," the hospital embraces an ethos of openness, collaboration, and mutual success. By leveraging both its own independent R&D capabilities and strategic partnerships with innovative global enterprises in medical biopharmaceuticals and devices, the hospital aims to accelerate the clinical translation and practical implementation of novel drugs, medical devices, and precision medical technologies. Ultimately, this endeavor seeks to meet the public's ever-growing demands for medical care, wellness, anti-aging solutions, and enhanced patient experiences, thereby contributing to the healthy and sustainable development of China's precision medicine sector.
博鳌恒大国际医院Boao Evergrande International Hospital
博鳌恒大国际医院医院占地121.8亩，总建筑面积11万平方米，包括医疗楼和康养楼两大区域。其中，医疗楼病房均为高标准单人间，可展开住院床位315张；康养楼区域配套190套高品质公寓，可展开康养床位424张。医院设有肿瘤科、放射医学科、预防保健科、医学检验科、医学影像科、健康体检中心等科室。医院配备有瓦里安TrueBeam直线加速器、西门子PET-CT、西门子3.0磁共振、西门子钼靶、64排128层螺旋CT、DR、彩超等大批先进、高端的仪器设备。医院整合国内外医疗专家、设备、特许药械和创新技术等医疗资源，以多学科会诊MDT诊疗模式为抓手，综合运用化疗、免疫、靶向、放疗等综合技术服务手段，持续专注于提高癌症患者的生存率与生活品质，致力于帮助国内外人群，享受到国际前沿的肿瘤治疗技术与健康管理方案。医疗楼病房均为高标准单人间，共设床位223张；康养楼区域配套190套高品质公寓，共设康养床位424张。其与丹娜法伯癌症研究院联合成立的丹娜法伯/布莱根癌症中心在全球肿瘤治疗领域占据领先地位。
The hospital occupies a site of 121.8 mu, with a total floor area of 110,000 square meters, comprising two main zones: a Medical Building and a Wellness & Rehabilitation Building. Specifically, the wards in the Medical Building consist entirely of high-standard private rooms, offering a capacity of 315 inpatient beds; the Wellness & Rehabilitation Building zone features 190 high-quality apartments, providing 424 beds for wellness and rehabilitation services.The hospital houses various departments, including Oncology, Radiation Medicine, Preventive Healthcare, Medical Laboratory, Medical Imaging, and a Health Examination Center. It is equipped with a comprehensive array of advanced, high-end medical instruments and equipment, such as the Varian TrueBeam linear accelerator, Siemens PET-CT, Siemens 3.0T MRI, Siemens mammography systems, a 64-row/128-slice spiral CT scanner, digital radiography (DR) systems, and color Doppler ultrasound units.By integrating medical resources—including domestic and international experts, equipment, licensed pharmaceuticals and medical devices, and innovative technologies—the hospital leverages a multidisciplinary team (MDT) consultation model as its core approach. Through the comprehensive application of therapeutic modalities such as chemotherapy, immunotherapy, targeted therapy, and radiotherapy, the hospital remains steadfastly focused on improving both the survival rates and quality of life for cancer patients. It is dedicated to enabling people from both China and abroad to access cutting-edge international oncology treatments and health management solutions.The wards within the Medical Building consist exclusively of high-standard private rooms, totaling 223 beds; the Wellness & Rehabilitation Building zone features 190 high-quality apartments, providing a total of 424 beds for wellness and rehabilitation services. Furthermore, the Dana-Farber/Brigham Cancer Center—established in collaboration with the Dana-Farber Cancer Institute—holds a leading position within the global field of oncology treatment.
The hospital occupies a site of 121.8 mu, with a total floor area of 110,000 square meters, comprising two main zones: a Medical Building and a Wellness & Rehabilitation Building. Specifically, the wards in the Medical Building consist entirely of high-standard private rooms, offering a capacity of 315 inpatient beds; the Wellness & Rehabilitation Building zone features 190 high-quality apartments, providing 424 beds for wellness and rehabilitation services.The hospital houses various departments, including Oncology, Radiation Medicine, Preventive Healthcare, Medical Laboratory, Medical Imaging, and a Health Examination Center. It is equipped with a comprehensive array of advanced, high-end medical instruments and equipment, such as the Varian TrueBeam linear accelerator, Siemens PET-CT, Siemens 3.0T MRI, Siemens mammography systems, a 64-row/128-slice spiral CT scanner, digital radiography (DR) systems, and color Doppler ultrasound units.By integrating medical resources—including domestic and international experts, equipment, licensed pharmaceuticals and medical devices, and innovative technologies—the hospital leverages a multidisciplinary team (MDT) consultation model as its core approach. Through the comprehensive application of therapeutic modalities such as chemotherapy, immunotherapy, targeted therapy, and radiotherapy, the hospital remains steadfastly focused on improving both the survival rates and quality of life for cancer patients. It is dedicated to enabling people from both China and abroad to access cutting-edge international oncology treatments and health management solutions.The wards within the Medical Building consist exclusively of high-standard private rooms, totaling 223 beds; the Wellness & Rehabilitation Building zone features 190 high-quality apartments, providing a total of 424 beds for wellness and rehabilitation services. Furthermore, the Dana-Farber/Brigham Cancer Center—established in collaboration with the Dana-Farber Cancer Institute—holds a leading position within the global field of oncology treatment.
海南博鳌金域国际医学检验中心Hainan Boao Kingmed International Medical Laboratory
广州金域医学检验集团股份有限公司（简称“金域医学”，股票代码：603882）是一家以第三方医学检验及病理诊断业务为核心的高科技服务企业，通过不断积累的“大平台、大网络、大服务、大样本和大数据”等核心资源优势，致力于为全国各级医疗机构提供领先的医学诊断信息整合服务，现已成为国内第三方医学检验行业的市场领先企业。金域医学严格遵循国际标准，建立先进的质量管理体系，获得包括美国CAP、中国CNAS、法国BV等国内外权威机构的认证认可证书110张，连续22年领先行业。通过自主创新、产学研协同创新和开放创新，金域医学可提供超4000项医学检测和病理诊断项目，检测结果可为全球70多个国家和地区认可。海南博鳌金域国际医学检验中心有限公司（简称“博鳌金域”）由金域医学在海南博鳌乐城国际医疗旅游先行区投资建设而成，是一家按照国际标准建设的第三方医学检测实验室。博鳌金域大楼建筑面积17578㎡，依托金域医学集团的技术平台和人才积累，转化引进国外已批准上市、国内未获批的医学检测新技术和新项目，探索与国内外IVD和药企等上游产业的合作模式。实验室目前开展的学科有基因测序室、生化室、化学发光室、微生物室、免疫室、血液室。
Guangzhou KingMed Diagnostics Group Co., Ltd. (referred to as "KingMed Diagnostics"; Stock Code: 603882) is a high-tech service enterprise centered on third-party medical testing and pathology diagnosis. Leveraging its continuously accumulated core resource advantages—encompassing "large-scale platforms, extensive networks, comprehensive services, vast sample repositories, and big data"—the company is dedicated to providing leading medical diagnostic information integration services to healthcare institutions of all levels across the country. It has now established itself as a market leader within China's third-party medical testing industry. Adhering strictly to international standards, KingMed Diagnostics has established an advanced quality management system and has obtained 110 certifications and accreditations from authoritative domestic and international bodies—including the U.S. CAP, China's CNAS, and France's BV—maintaining its industry leadership for 22 consecutive years. Through independent innovation, collaborative innovation involving industry, academia, and research, and open innovation, KingMed Diagnostics offers over 4,000 medical testing and pathology diagnosis items, with test results recognized in more than 70 countries and regions worldwide.Hainan Boao KingMed International Medical Laboratory Co., Ltd. (hereinafter referred to as "Boao KingMed") was established and built by KingMed Diagnostics within the Hainan Boao Lecheng International Medical Tourism Pilot Zone. It is a third-party medical testing laboratory constructed in accordance with international standards. The Boao KingMed facility spans a total floor area of 17,578 square meters. Leveraging the technical platforms and accumulated talent of the KingMed Diagnostics Group, the facility focuses on translating and introducing novel medical testing technologies and projects—specifically those approved for market use abroad but not yet approved domestically—while simultaneously exploring collaborative models with upstream industries, such as domestic and international IVD manufacturers and pharmaceutical companies. The laboratory currently operates specialized departments covering gene sequencing, biochemistry, chemiluminescence, microbiology, immunology, and hematology.
Guangzhou KingMed Diagnostics Group Co., Ltd. (referred to as "KingMed Diagnostics"; Stock Code: 603882) is a high-tech service enterprise centered on third-party medical testing and pathology diagnosis. Leveraging its continuously accumulated core resource advantages—encompassing "large-scale platforms, extensive networks, comprehensive services, vast sample repositories, and big data"—the company is dedicated to providing leading medical diagnostic information integration services to healthcare institutions of all levels across the country. It has now established itself as a market leader within China's third-party medical testing industry. Adhering strictly to international standards, KingMed Diagnostics has established an advanced quality management system and has obtained 110 certifications and accreditations from authoritative domestic and international bodies—including the U.S. CAP, China's CNAS, and France's BV—maintaining its industry leadership for 22 consecutive years. Through independent innovation, collaborative innovation involving industry, academia, and research, and open innovation, KingMed Diagnostics offers over 4,000 medical testing and pathology diagnosis items, with test results recognized in more than 70 countries and regions worldwide.Hainan Boao KingMed International Medical Laboratory Co., Ltd. (hereinafter referred to as "Boao KingMed") was established and built by KingMed Diagnostics within the Hainan Boao Lecheng International Medical Tourism Pilot Zone. It is a third-party medical testing laboratory constructed in accordance with international standards. The Boao KingMed facility spans a total floor area of 17,578 square meters. Leveraging the technical platforms and accumulated talent of the KingMed Diagnostics Group, the facility focuses on translating and introducing novel medical testing technologies and projects—specifically those approved for market use abroad but not yet approved domestically—while simultaneously exploring collaborative models with upstream industries, such as domestic and international IVD manufacturers and pharmaceutical companies. The laboratory currently operates specialized departments covering gene sequencing, biochemistry, chemiluminescence, microbiology, immunology, and hematology.
中国干细胞集团海南博鳌附属干细胞医院China Stem Cell Group Affiliated Stem Cell Hospital Hainan
中国干细胞集团联合上海交通大学医学院附属同仁医院在博鳌乐城国际医疗旅游先行区建成了中国干细胞集团海南博鳌附属干细胞医院暨上海交通大学医学院附属同仁医院博鳌分院，并先后冠名苏州大学附属儿童医院博鳌分院、海南省红十字干细胞医院。医院是国家卫健委批准执业的三级医院，属于医疗机构的最高等级，是海南省医保定点单位。医院按照JCI国际标准建设，致力于干细胞治疗和再生医学临床转化，被公认为国内规模最大、技术最先进的干细胞医院。医院总建筑面积约30000平方米，包括由A、B、C三栋大楼组成的医院主楼，面积约25000平方米；以及一栋独立的院士楼，面积约5000平方米。设有医疗、科研、行政办公等功能。其中，医疗区规划设有100间百级无菌层流病房、普通床位235张，均为高标准VIP房间；科研区设有院士工作站，包括GMP标准实验室、干细胞库、学术报告厅和院士办公室。医院已开设包括内科、外科、妇产科、皮肤科、医学美容科、肿瘤科、血液内科、小儿血液科、预防保健、神经外科、骨科等，其中儿童血液病和成人亚健康调理代表了国内前沿医疗服务水平。医院现有MVE1900系列气相液氮储存系统、百级无菌层流病房、流式细胞仪、程控降温仪、微生物检测系统、微量超高速离心机、细菌培养箱、Bio-Rad ChemDoc化学发光成像系统等医疗设备和科研设备。已建成全国规模最大的干细胞公共资源库，全球华人配型成功率100％。干细胞移植已超7209例，重症晚期恶性血液肿瘤患者五年生存率60.35%，代表国际领先水平。
The China Stem Cell Group, in collaboration with Renji Hospital affiliated to Shanghai Jiao Tong University School of Medicine, has established the China Stem Cell Group Hainan Boao Affiliated Stem Cell Hospital—also known as the Boao Branch of Renji Hospital—within the Boao Lecheng International Medical Tourism Pilot Zone. Subsequently, the facility was also designated as the Boao Branch of the Children's Hospital Affiliated to Soochow University and the Hainan Red Cross Stem Cell Hospital. Approved for operation by the National Health Commission, the hospital is classified as a Grade III hospital—the highest tier for medical institutions—and serves as a designated provider for Hainan Province's medical insurance system. Constructed in strict adherence to JCI international standards, the hospital is dedicated to the clinical translation of stem cell therapies and regenerative medicine, and is widely recognized as the largest and most technologically advanced stem cell hospital in China.The hospital encompasses a total floor area of approximately 30,000 square meters. This comprises the main hospital complex—consisting of three interconnected buildings (A, B, and C) with an area of approximately 25,000 square meters—and a separate, standalone "Academician Building" covering approximately 5,000 square meters. The facility integrates functions for medical services, scientific research, and administrative operations. Specifically, the medical zone is designed to feature 100 Class 100 sterile laminar-flow wards and 235 general inpatient beds, all of which are configured as high-standard VIP rooms. The research zone houses an Academician Workstation, which includes GMP-compliant laboratories, a stem cell bank, an academic lecture hall, and private offices for academicians.The hospital currently offers a comprehensive range of clinical departments, including Internal Medicine, Surgery, Obstetrics and Gynecology, Dermatology, Medical Aesthetics, Oncology, Hematology, Pediatric Hematology, Preventive Healthcare, Neurosurgery, and Orthopedics. Notably, its services in pediatric hematological diseases and the management of adult sub-health conditions represent the forefront of medical care within the country.The facility is equipped with state-of-the-art medical and research instrumentation, including the MVE 1900 Series vapor-phase liquid nitrogen storage system, Class 100 sterile laminar flow wards, flow cytometers, programmable rate freezers, microbial detection systems, ultra-high-speed microcentrifuges, bacterial incubators, and the Bio-Rad ChemDoc chemiluminescence imaging system.The hospital has established the largest public stem cell bank in the nation, boasting a 100% success rate for donor matching among the global Chinese population. To date, the institution has performed over 7,209 stem cell transplants; for patients with severe, late-stage hematological malignancies, the five-year survival rate stands at 60.35%, a figure that represents a leading standard in international medical practice.
The China Stem Cell Group, in collaboration with Renji Hospital affiliated to Shanghai Jiao Tong University School of Medicine, has established the China Stem Cell Group Hainan Boao Affiliated Stem Cell Hospital—also known as the Boao Branch of Renji Hospital—within the Boao Lecheng International Medical Tourism Pilot Zone. Subsequently, the facility was also designated as the Boao Branch of the Children's Hospital Affiliated to Soochow University and the Hainan Red Cross Stem Cell Hospital. Approved for operation by the National Health Commission, the hospital is classified as a Grade III hospital—the highest tier for medical institutions—and serves as a designated provider for Hainan Province's medical insurance system. Constructed in strict adherence to JCI international standards, the hospital is dedicated to the clinical translation of stem cell therapies and regenerative medicine, and is widely recognized as the largest and most technologically advanced stem cell hospital in China.The hospital encompasses a total floor area of approximately 30,000 square meters. This comprises the main hospital complex—consisting of three interconnected buildings (A, B, and C) with an area of approximately 25,000 square meters—and a separate, standalone "Academician Building" covering approximately 5,000 square meters. The facility integrates functions for medical services, scientific research, and administrative operations. Specifically, the medical zone is designed to feature 100 Class 100 sterile laminar-flow wards and 235 general inpatient beds, all of which are configured as high-standard VIP rooms. The research zone houses an Academician Workstation, which includes GMP-compliant laboratories, a stem cell bank, an academic lecture hall, and private offices for academicians.The hospital currently offers a comprehensive range of clinical departments, including Internal Medicine, Surgery, Obstetrics and Gynecology, Dermatology, Medical Aesthetics, Oncology, Hematology, Pediatric Hematology, Preventive Healthcare, Neurosurgery, and Orthopedics. Notably, its services in pediatric hematological diseases and the management of adult sub-health conditions represent the forefront of medical care within the country.The facility is equipped with state-of-the-art medical and research instrumentation, including the MVE 1900 Series vapor-phase liquid nitrogen storage system, Class 100 sterile laminar flow wards, flow cytometers, programmable rate freezers, microbial detection systems, ultra-high-speed microcentrifuges, bacterial incubators, and the Bio-Rad ChemDoc chemiluminescence imaging system.The hospital has established the largest public stem cell bank in the nation, boasting a 100% success rate for donor matching among the global Chinese population. To date, the institution has performed over 7,209 stem cell transplants; for patients with severe, late-stage hematological malignancies, the five-year survival rate stands at 60.35%, a figure that represents a leading standard in international medical practice.
海南博尔医学中心Hainan Bo Er Medical Center
海南博尔医学中心，秉承大医治未病，未病先防，已病防变，以预防医学的理念为建立初衷，2016年在博鳌乐城国际医疗旅游先行区立项审批通过，依据海南省卫计委28号文及自有知识产权发明专利技术 ZL 03.1 55833.X开展“自体成纤维前体细胞治疗术”；依据海南省卫计委28号文和与东京大学签订的技术合作协议及授权开展“CAL”自体脂肪干细胞移植术。同时积极推进乐城医疗先行区特有的“1+X”共享医院模式运作。
Hainan Bo'er Medical Center was established with the foundational philosophy of preventive medicine—encapsulated in the maxim "a great physician treats the disease before it manifests"—aiming to prevent illness before onset and to halt its progression once present. Approved as a project within the Boao Lecheng International Medical Tourism Pilot Zone in 2016, the Center conducts "Autologous Fibroblast Precursor Cell Therapy" in accordance with Document No. 28 issued by the Hainan Provincial Health and Family Planning Commission, utilizing its own proprietary patented technology (Patent No. ZL 03.1 55833.X). Furthermore, acting under the authority of Document No. 28 and a technical cooperation agreement signed with the University of Tokyo, the Center performs "CAL" Autologous Adipose Stem Cell Transplantation. Concurrently, the Center actively promotes the operational implementation of the "1+X" Shared Hospital Model—a unique feature of the Lecheng Medical Pilot Zone.
Hainan Bo'er Medical Center was established with the foundational philosophy of preventive medicine—encapsulated in the maxim "a great physician treats the disease before it manifests"—aiming to prevent illness before onset and to halt its progression once present. Approved as a project within the Boao Lecheng International Medical Tourism Pilot Zone in 2016, the Center conducts "Autologous Fibroblast Precursor Cell Therapy" in accordance with Document No. 28 issued by the Hainan Provincial Health and Family Planning Commission, utilizing its own proprietary patented technology (Patent No. ZL 03.1 55833.X). Furthermore, acting under the authority of Document No. 28 and a technical cooperation agreement signed with the University of Tokyo, the Center performs "CAL" Autologous Adipose Stem Cell Transplantation. Concurrently, the Center actively promotes the operational implementation of the "1+X" Shared Hospital Model—a unique feature of the Lecheng Medical Pilot Zone.
海南新生泉医院Hainan Xinshengquan Hospital
海南新生泉医院是亚洲干细胞集团旗下的医疗转化平台，于2015年获批入驻海南博鳌乐城国际医疗旅游先行区。医院依托先进的生命科学生物医药技术研发能力，围绕心血管健康、肿瘤预防、脑健康、骨关节养护、生殖健康等开发了以生命科学、特许药械为核心的系统性预防诊疗调养方案，为客户提供个性化医疗定制服务，拥有集治疗、调理、康复为一体的健康管理医疗产业化综合平台。
Hainan Xinshengquan Hospital serves as the medical translation platform of the Asia Stem Cell Group; it was approved to establish operations within the Hainan Boao Lecheng International Medical Tourism Pilot Zone in 2015. Leveraging advanced R&D capabilities in life sciences and biomedicine, the hospital has developed comprehensive programs for prevention, diagnosis, treatment, and wellness—centered on life sciences and authorized medical devices—that address key areas such as cardiovascular health, cancer prevention, brain health, musculoskeletal care, and reproductive health. By offering personalized, bespoke medical services to its clients, the hospital functions as an integrated, industrialized healthcare platform that seamlessly combines treatment, wellness management, and rehabilitation.
Hainan Xinshengquan Hospital serves as the medical translation platform of the Asia Stem Cell Group; it was approved to establish operations within the Hainan Boao Lecheng International Medical Tourism Pilot Zone in 2015. Leveraging advanced R&D capabilities in life sciences and biomedicine, the hospital has developed comprehensive programs for prevention, diagnosis, treatment, and wellness—centered on life sciences and authorized medical devices—that address key areas such as cardiovascular health, cancer prevention, brain health, musculoskeletal care, and reproductive health. By offering personalized, bespoke medical services to its clients, the hospital functions as an integrated, industrialized healthcare platform that seamlessly combines treatment, wellness management, and rehabilitation.
Page updated
Google Sites
Report abuse